Forsta AP Fonden Lowers Stake in United Therapeutics Co. (NASDAQ:UTHR)

Forsta AP Fonden lessened its stake in United Therapeutics Co. (NASDAQ:UTHR) by 14.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,400 shares of the biotechnology company’s stock after selling 1,300 shares during the period. Forsta AP Fonden’s holdings in United Therapeutics were worth $2,357,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the period. Access Investment Management LLC grew its stake in United Therapeutics by 0.8% in the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock worth $2,314,000 after purchasing an additional 55 shares in the last quarter. MBM Wealth Consultants LLC increased its holdings in United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 59 shares during the period. Fifth Third Bancorp raised its position in United Therapeutics by 13.2% during the 2nd quarter. Fifth Third Bancorp now owns 585 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 68 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of United Therapeutics by 3.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company’s stock worth $849,000 after buying an additional 81 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR stock opened at $339.12 on Monday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $366.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 1.23 and a beta of 0.57. The stock’s 50-day simple moving average is $336.73 and its 200-day simple moving average is $287.95.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $5.24 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on UTHR shares. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. Oppenheimer increased their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. Finally, TD Cowen boosted their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $350.36.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $313.91, for a total transaction of $1,130,076.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $40,808.30. The disclosure for this sale can be found here. Insiders have sold a total of 114,522 shares of company stock valued at $37,671,474 in the last ninety days. Company insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.